Louisiana State Employees Retirement System Has $497,000 Stock Holdings in Schrödinger, Inc. (NASDAQ:SDGR)

Louisiana State Employees Retirement System trimmed its holdings in Schrödinger, Inc. (NASDAQ:SDGR) by 3.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,800 shares of the company’s stock after selling 1,000 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Schrödinger were worth $497,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Texas Permanent School Fund Corp raised its holdings in shares of Schrödinger by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 47,869 shares of the company’s stock valued at $1,292,000 after buying an additional 626 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Schrödinger by 49.5% in the second quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after buying an additional 703 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Schrödinger by 7.4% in the first quarter. ProShare Advisors LLC now owns 10,987 shares of the company’s stock valued at $297,000 after buying an additional 753 shares during the last quarter. Illinois Municipal Retirement Fund raised its holdings in shares of Schrödinger by 2.7% in the first quarter. Illinois Municipal Retirement Fund now owns 32,043 shares of the company’s stock valued at $865,000 after buying an additional 831 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Schrödinger by 145.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,413 shares of the company’s stock valued at $27,000 after buying an additional 837 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

SDGR has been the topic of a number of research reports. KeyCorp cut their target price on shares of Schrödinger from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Morgan Stanley reduced their target price on shares of Schrödinger from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 21st. Finally, BMO Capital Markets lowered their target price on shares of Schrödinger from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

Insider Activity

In other news, insider Margaret Dugan sold 1,531 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total value of $27,221.18. Following the completion of the transaction, the insider now owns 13,469 shares of the company’s stock, valued at $239,478.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.60% of the stock is owned by company insiders.

Schrödinger Stock Down 1.9 %

Shares of SDGR stock opened at $17.89 on Wednesday. Schrödinger, Inc. has a 12-month low of $16.67 and a 12-month high of $38.00. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -6.68 and a beta of 1.50. The firm has a fifty day moving average of $18.91 and a 200-day moving average of $20.61.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.